The U.S. Centers for Disease Control and Prevention panel of vaccine experts will vote on shots for respiratory syncytial ...

A scientist in charge of Covid-19 and respiratory syncytial virus data has abruptly resigned, telling colleagues she doesn’t ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...

Respiratory Syncytial Virus is a growing health concern for Indian infants. Efforts for maternal RSV vaccine faces challenges ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants.

The U.S. is seeing a "quad-demic" as cases of COVID-19, flu, RSV and norovirus spread at the same time. Experts said this is what you need to know. The so-called "quad-demic" includes flu ...

RSV is responsible for around 1 lakh deaths, over 3.6 million hospitalisations in children under age of 5 every year, ...

The incidence of RSV across 5 respiratory virus seasons was substantial among adult patients with high-risk underlying conditions.

The FDA approved the monoclonal antibody clesrovimab-cfor for the prevention of respiratory syncytial virus lower respiratory ...

Estimates varied from 2008 through 2018, with RSV-associated antibiotic prescribing exceeding 10% in peak RSV years and ...